PUBLICATION

Global Business Reports

AUTHORS

Irina Negoita, Harriet Bailey, Neha Ghanshamdas, James Hogan

United States Pharmaceuticals 2015

October 09, 2015

The United States has long been the land of the American Dream—the opportunity available to all citizens to improve their quality of life with hard work and determination. A key theme in numerous works of classical American literature, it unites traditional opponents through its shared ideal that the next generation will enjoy prosperity not yet attained by the previous one.

Although often attributed to the pursuit of consumer goods, money and property, the American Dream clearly underpins the ideals at the heart of the U.S. pharmaceutical industry. In its relentless attempts to create drugs to improve an individual’s health, prolong life and eradicate disease for future generations, Americans are able to harness their talents and energy to transform lives.

The United States leads the world in terms of research and development (R&D); spending on this area by research-based pharmaceutical companies amounts to more than 20% of sales, compared to an average of 17% in the European Union. The importance of the sector to the American psyche is evident when compared with other high-technology industries: annual spending by the pharmaceutical industry is five times greater than in aerospace, four and a half times more than in the chemicals industry and two and a half times more than in the software and computer services industries.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Québec and Atlantic Canada Mining 2025

Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER